Bladder Cancer Clinical Trial

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

Summary

Prospective observational study to validate the performance characteristics and clinical utility of Cxbladder tests in a Veterans Affairs cohort.

View Full Description

Full Description

Non-invasive, voided urine sample used for both Cxbladder molecular tests, voided urine sample may be used for standard of care testing. Retrospective analysis of data after study completion ensures a de-phasing of study sample analysis from clinical decision making; patient treatment and management.

The study aims to sequentially recruit up to 1000 patients presenting for assessment of hematuria (microscopic or macroscopic) by cystoscopy across multiple Veterans Affairs sites

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria patients referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.
Able to provide a voided urine sample of the required minimum volume
Able to give written consent
Able and willing to comply with study requirements
Aged 18 years or older

Exclusion Criteria:

Prior history of bladder malignancy, prostate or renal cell carcinoma
Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection
Previous alkylating based chemotherapy
Known Pregnancy.

Study is for people with:

Bladder Cancer

Estimated Enrollment:

1000

Study ID:

NCT04943380

Recruitment Status:

Recruiting

Sponsor:

Pacific Edge Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Veterans Medical Research Foundation
San Diego California, 92161, United States More Info
Kyoko Sakamoto, MD
Contact
858-642-1190
[email protected]
Raj Rajasekaran, PhD
Contact
858-552-8585
[email protected]
Kyoko Sakamoto, MD
Principal Investigator
Raj Rajasekaran, PhD
Sub-Investigator
Minneapolis VA Health Care System
Minneapolis Minnesota, 55417, United States More Info
Michael Risk
Principal Investigator
NWIHCS-Omaha VA Medical Center
Omaha Nebraska, 68105, United States More Info
Holly DeSpiegelaere
Contact
George Hemstreet
Principal Investigator
Oklahoma City VA Hospital
Oklahoma City Oklahoma, 73104, United States More Info
Seerat Moutassam
Contact
405-456-1775
[email protected]
Kelly Stratton
Principal Investigator
Medical University of South Carolina
Charleston South Carolina, 29401, United States More Info
Susan Caulder
Contact
843-789-7816
[email protected]
Steve Savage
Principal Investigator
White River Junction VAMC
White River Junction Vermont, 05009, United States More Info
Jason C Laubach
Contact
[email protected]
Florian R Schroeck, MD, MS
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

1000

Study ID:

NCT04943380

Recruitment Status:

Recruiting

Sponsor:


Pacific Edge Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.